繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation Of Non-Human Primate Data For ORX142 At Sleep Europe 2024

2024-08-27 20:13

Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late- breaking poster presentation at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) being held September 24-27, 2024, in Seville, Spain.

 

The poster presentation will feature, for the first time, robust preclinical data demonstrating that low doses of ORX142 promoted wakefulness in non-human primates in a highly predictive and translational model.

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。